Pfizer and Myovant Report Results of Relugolix Combination Therapy in P-III LIBERTY Withdrawal Study in Women with Uterine Fibroids
Shots:
- The P-III LIBERTY withdrawal study involves assessing Relugolix combination therapy [relugolix (40 mg) + estradiol (1.0mg) & norethindrone acetate (0.5mg)] vs PBO in women with uterine fibroids for 24wks.
- The study met its 1EPs i.e. achieving the sustained responder rate @76wks. (menstrual blood loss < 80 mL) (78.4% vs 15.1%). The study met 2EPs i.e. sustained responder rate @2yrs. (69.8%)- 88.3% of women who discontinued treatment @52wks. relapsed with heavy menstrual bleeding- with a median time of return to heavy menstrual bleeding of 5.9wks.
- Relugolix combination tablet is under review from US FDA with an anticipated PFUFA date is Jun 01- 2021
Ref: Pfizer | Image: Bloomberg Quint
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com